Investigating long-term effects of COVID-19
Assessment of Post COVID-19 Manifestations in a Multicenter Cohort Study (EuCARE-POSTCOVID Study)
Euresist Network GEIE · NCT05531773
This study looks at people who have recovered from COVID-19 to see what long-term symptoms they might still have and what factors could affect their recovery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Euresist Network GEIE (other) |
| Locations | 7 sites (Düsseldorf and 6 other locations) |
| Trial ID | NCT05531773 on ClinicalTrials.gov |
What this trial studies
The EuCARE-POSTCOVID study is an observational multicenter initiative that enrolls patients who have recovered from the acute phase of COVID-19 to explore the prevalence and predictors of post COVID-19 condition. This study will utilize both retrospective data from existing post COVID-19 outpatient services and a prospective cohort approach. A multidisciplinary team, including clinicians and epidemiologists, will analyze the clinical course and long-term outcomes of COVID-19 patients, focusing on the persistence of symptoms that may arise after recovery. The study aims to provide insights into the impact of different viral variants and the effectiveness of various containment strategies.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years old who have had a confirmed diagnosis of COVID-19, regardless of the severity of their initial illness.
Not a fit: Patients who have declined to participate or who died during hospitalization will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of post COVID-19 condition and improve management strategies for affected patients.
How similar studies have performed: Other studies have indicated a high prevalence of post COVID-19 symptoms, suggesting that this approach is relevant and builds on existing knowledge.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients, \>18 years old; * Confirmed diagnosis of COVID-19 disease (positive SARS CoV-2 RNA on naso- pharyngeal swab or upper respiratory sample); * Mild COVID-19 disease without hospital admission or moderate/severe disease requiring hospital admission for COVID-19 or hospitalization for other medical issues with a positive SARS CoV-2 RNA sample; * Informed consent for the study. Exclusion Criteria: * death during hospitalization: * patient's decline to participate in the study.
Where this trial is running
Düsseldorf and 6 other locations
- University Hospital Heinrich Heine — Düsseldorf, Germany (RECRUITING)
- Policlinico "Tor Vergata", Università degli Studi di Roma TOR VERGATA — Rome, Lazio, Italy (RECRUITING)
- ASST Santi Paolo e Carlo — Milan, Lombardy, Italy (RECRUITING)
- Vilnius University Hospital, Santaros Klinikos — Vilnius, Lithuania (RECRUITING)
- Regional Hospital Dr. Juan Graham Casasús — Villahermosa, Tabasco, Mexico (RECRUITING)
- Centro Hospitalar de Lisboa Ocidental — Lisbon, Portugal (RECRUITING)
- St. Mary Hospital, Imperial College Healthcare NHS Trust — London, United Kingdom (RECRUITING)
Study contacts
- Study coordinator: FRANCESCA INCARDONA, DR
- Email: francesca.incardona@euresist.org
- Phone: +393356112830
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: COVID-19